Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





PROPYLENE GLYCOL DINITRATE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 6423-43-4; **Chemical Formula:** C3H6N2O6
OSHA previously had no exposure limit for propylene glycol dinitrate. The ACGIH recommends a TLV-TWA of 0.05 ppm, with a skin notation. The Agency proposed a permissible exposure limit of 0.05 ppm TWA, with a skin notation, for this substance, and NIOSH (Ex. 8-47, Table N1) concurred with the proposed limit. The final rule establishes a PEL of 0.05 ppm but does not include the proposed skin notation. When freshly prepared, propylene glycol dinitrate is a colorless liquid with a disagreeable odor.
Exposure to this substance affects blood pressure, causes methemoglobinuria and respiratory toxicity, injures liver and kidney tissues, and distorts vision. Propylene glycol dinitrate can also cause headache and incoordination.
The oral LD(50) value for the rat is between 480 and 250 mg/kg (Clark and Litchfield 1969/Ex. 1-543; Andersen and Mehl 1973/Ex. 1-536), and the subcutaneous LD(50) is 530 mg/kg (Andersen and Mehl 1973/Ex. 1-536). Mice are reported to be somewhat more resistant, with a subcutaneous LD(50) of slightly more than 1200 mg/kg; however, cats appear to be even more susceptible to propylene glycol dinitrate and exhibit a subcutaneous LD(50) of between 200 and 300 mg/kg (Clark and Litchfield 1969/Ex. 1-543). In all species studied, death occurs by anoxia, which is caused by almost complete conversion of hemoglobin to methemoglobin (Clark and Litchfield 1969/Ex. 1-543). Skin tests in albino rabbits did not produce irritation, but ocular instillation caused transient conjunctival redness (Jones, Strickland, and Siegel 1972/ Ex. 1-742). Twenty-day skin exposures in rabbits at 1 g/kg caused minor irritation, and at 2 g/kg, rabbits became weak and cyanotic; one of five rabbits died, and this animal’s hemoglobin and hematocrit values had decreased. When the dose was increased to 4 g/kg, the rabbits’ methemoglobin values rose to 34.5 percent at death (Jones, Strickland, and Siegel 1972/ Ex. 1-742). Continuous 90-day inhalation exposures at 10 ppm caused kidney and liver changes in dogs; exposures at 35 ppm caused heavy iron deposits in the liver, spleen, and kidneys. Female (but not male) rats showed a drop in blood pressure within 30 minutes after injection of doses above 5 mg/kg. Rhesus monkeys displayed mydriasis in 90-day exposures at 35 ppm but no change in avoidance behavior during a visual discrimination and acuity threshold test (Jones, Strickland, and Siegel 1972/ Ex. 1-742).
In humans, eight-hour exposures to 0.2 ppm or higher concentrations of propylene glycol dinitrate resulted in visual distortion and headache (Stewart, Peterson, Newton et al. 1974, as cited in ACGIH 1986/Ex. 1-3, p. 502). Although subjects developed a tolerance for the headache response, the visual effects were cumulative. Impaired balance occurred after 6.5 hours of exposure to 0.5 ppm, and a 40-minute exposure to 1.5 ppm caused eye irritation. Subjects exposed at 0.5 ppm for 8 hours experienced a consistent elevation in diastolic pressure but no pulmonary irritation. At concentrations of 0.03 to 1.5 ppm, no hematologic effects were observed (Stewart, Peterson, Newton et al. 1974, as cited in ACGIH 1986/Ex. 1-3, p. 502). Studies of human exposures to levels below 0.1 ppm do not report chronic neurotoxicity (Horvath, Ilka, Boyd, and Markhan 1981/Ex. 1-557).
The skin notation included in the proposal for this substance is not included in the final rule because evidence demonstrates that the dermal LD(50) in rabbits is even greater than 2 g/kg (see the discussion in Section VI.C.18 for OSHA’s policy on skin notations). No comments except those from NIOSH were received on the health effects of propylene glycol dinitrate.
OSHA is establishing an 8-hour TWA limit of 0.05 ppm for propylene glycol dinitrate. The Agency concludes that this limit will protect workers against the significant risks of hepatotoxic, hematologic, and central nervous system effects (all of which constitute material health impairments) that exist from workplace exposure at the levels permitted in the absence of any OSHA PEL.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue